A Phase 3 interventional study of fluvastatin, ezetimibe in Dyslipidemia, sponsored by Novartis. Completed at 1 site in Spain. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2011-11-08.
Sponsored by Novartis · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing ezetimibe in Dyslipidemias — 3 open to participants now, 3 under way, none of them phase 3. Ezetimibe · Dyslipidemias.
Among the 18 studies testing ezetimibe in Dyslipidemias, this one is the 7th largest by enrollment, is the only one that started in 2003, is the only one in phase 3, and was the 1st registered.
1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.
Browse Dyslipidemias studies →3 of the 18 studies testing ezetimibe in Dyslipidemias are open now, in 2 countries. Recruiting first, the newest first:
Korea University Anam Hospital · Sites in Korea, Republic of
Ages 19+
Cairo University · Sites in Egypt
Ages 18–100
University of Salerno
Ages 18+
By country, each count listing its studies:
Ezetimibe: first FDA approval 2002 (ZETIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 83 is below the median of 100 across 986 interventional studies indexed under Dyslipidemias.
Median enrollment 65 across the 18 interventional studies. Of the 15 that completed or were terminated, 4 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 18 have an industry lead sponsor. The 10 most frequent:
Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
27 studies in Dyslipidemias by Novartis: 5 open now, 10 under way, 5 of them phase 3. Of 17 finished, 4 (24%) have results posted.
Among the 27 studies in Dyslipidemias by Novartis, this one is the 18th largest by enrollment of the 22 interventional ones that give a count, is the only one that started in 2003, is one of 8 in phase 3, and was the 2nd registered.
Novartis’s Dyslipidemias studies by the year they started, since 2001.
1 of the studies testing ezetimibe in Dyslipidemias that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04701242Cairo UniversityEzetimibe Utilization Early After Acute Myocardial Infarction, "EzAMI Trial" | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies testing ezetimibe in Dyslipidemias, from their registry updates:
Among Novartis’s 27 in Dyslipidemias:
This tab as a report to print or save as PDF → With an account.
The objective of this study is to assess the effect of the combination treatment on C-reactive protein and inflammatory markers as well as the safety and tolerability in a Spanish population
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol defined in and exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug pages: Fluvastatin · Ezetimibe
Change from baseline in low density lipoprotein cholesterol after 12 weeks
Change from baseline in total triglyceride, high density lipoprotein cholesterol, and composition of low density lipoprotein cholesterol after 12 weeks
Change from baseline in circulating marker of inflammation after 12 weeks
The record gives a start of Aug 2003, a primary completion of Aug 2005 and a completion of Aug 2005. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Fluvastatin · Ezetimibe